Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brain structural and functional alterations in MOG antibody disease.
Zhuo Z, Duan Y, Tian D, Wang X, Gao C, Ding J, Zheng F, Zhang T, Zhang X, Barkhof F, Shi FD, Liu Y. Zhuo Z, et al. Among authors: zheng f. Mult Scler. 2021 Aug;27(9):1350-1363. doi: 10.1177/1352458520964415. Epub 2020 Oct 15. Mult Scler. 2021. PMID: 33054621
Subtyping relapsing-remitting multiple sclerosis using structural MRI.
Zhuo Z, Li Y, Duan Y, Cao G, Zheng F, Ding J, Tian D, Wang X, Wang J, Zhang X, Li K, Zhou F, Huang M, Li Y, Li H, Zeng C, Zhang N, Sun J, Yu C, Han X, Haller S, Barkhof F, Shi F, Liu Y. Zhuo Z, et al. Among authors: zheng f. J Neurol. 2021 May;268(5):1808-1817. doi: 10.1007/s00415-020-10376-7. Epub 2021 Jan 2. J Neurol. 2021. PMID: 33387013
Cerebellar connectome alterations and associated genetic signatures in multiple sclerosis and neuromyelitis optica spectrum disorder.
Yang Y, Li J, Li T, Li Z, Zhuo Z, Han X, Duan Y, Cao G, Zheng F, Tian D, Wang X, Zhang X, Li K, Zhou F, Huang M, Li Y, Li H, Li Y, Zeng C, Zhang N, Sun J, Yu C, Shi F, Asgher U, Muhlert N, Liu Y, Wang J. Yang Y, et al. Among authors: zheng f. J Transl Med. 2023 May 27;21(1):352. doi: 10.1186/s12967-023-04164-w. J Transl Med. 2023. PMID: 37245044 Free PMC article.
Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X, Huang J, Sun S, Zhou D, Zhang B, Fang S, Zheng F, Li C, Wang X, Huang W, Wang L, He Q, Fu H, Zhang Y, Liu C, Dong L, Zhao X, Xu L, Sun X, Fan B, Song L, Zhou Z, Yu J, Li H. Man X, et al. Among authors: zheng f. Clin Transl Med. 2024 May;14(5):e1687. doi: 10.1002/ctm2.1687. Clin Transl Med. 2024. PMID: 38738791 Clinical Trial.
4,035 results